Florida Attorney General James Uthmeier has filed a state-court action against Pfizer and its CEO, Albert Bourla, alleging the company misled consumers about the safety and effectiveness of Pfizer’s COVID-19 vaccine. The suit adds a high-profile state enforcement action to the already complex body of litigation stemming from pandemic-era vaccine marketing, and it could become a closely watched test of how far state consumer-protection laws can reach in disputes over pharmaceutical communications.

At its core, the case appears to frame vaccine-related statements not simply as scientific or regulatory matters, but as actionable representations to consumers.

A federal judge in Connecticut has declined to pause the multistate antitrust litigation accusing generic-drug manufacturers of price-fixing, even as settlement discussions continue. The decision keeps one of the most closely watched coordinated state enforcement actions on an active track, preserving litigation pressure while negotiations unfold in parallel.

The case is part of the long-running generic-drug pricing litigation brought by a coalition of state attorneys general against multiple manufacturers.